에 대한 최신 뉴스 Aptiv (NYSE:APTV) 주식

Aptiv

Aptiv PLC signal and power solutions segment supplies components and systems that make up a vehicle's electrical system, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, driver-assist technologies, and displays, as well as the development of software for these systems.

News

Movers

APTV

RACE

TSLA

뱅크오브아메리카는 2025년에 실적이 개선될 것으로 예상되는 주요 자동차 주식 3종목으로 페라리(RACE), 앱티브(NYSE:APTV) 및 오토네이션(NYSE:AN)을 선정했다. 이들 기업은 최근의 변동성과 섹터 내 과제에도 불구하고 자동차 산업의 지속적인 추세로부터 혜택을 받을 수 있는 좋은 위치에 있다고 강조했다.

뱅크오브아메리카: 2025년 상승할 자동차 주식 3종목은?

AAUKF

ATSG

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

FFIV

KRON

MEIP

NISTF

PARA

PARIS:SGO

ROIC

SAVE

SHEL

SLGWF

SLNG

TRIP

TSX:SGO

ULCC

새로 등장한 블록 에볼런트 헬스(NYSE:EVH)가 매물로 나온 것으로 알려졌다. 버지니아 주 알링턴에 본사를 둔 이 소프트웨어 회사는 인수 문의를 받은 후 경매 프로세스를 시작했다. 잠재적인 구혼자 중에는 TPG(NASDAQ:TPG), 클레이톤, 듀블리에 &amp; 라이스(Clayton, Dubilier &amp; Rice), KKR &amp; 컴퍼니(NYSE:KKR)가 있다. 로이터는 건강 보험사 엘레반스 헬스(NYSE:ELV)가 한 사모 펀드 파트너와 협력하여 거래를 추진할 수 있다고 보고했다.

딜 디스패치: 쉘, 유니레버 외에도 매각 뉴스; 어니언이 알렉스 존스의 인포워스 인수 등

Large Cap

Trading Ideas

BORR

CHKP

MPWR

SMCI

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 슈퍼 마이크로 컴퓨터(NASDAQ:SMCI)의 주식은 독립 감사인인 언스터 &amp; 영(Ernst &amp; Young)의 사임 소식이 전해진 후 44.89% 하락했다. 아거스 리서치(Argus Research)는 매수에서 보유로 등급을 하향 조정했다.

슈퍼 마이크로 및 에스티 로더는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (10월 28일-11월 1일)

Aptiv PLC

WIIM

Agnico Eagle Mines shares are trading higher after Scotiabank maintained a Sector Outperform rating on the stock and raised its price target from $103 to $105.

United Airlines Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) will be reporting its fourth-quarter earnings on Tuesday. Wall Street expects $2.99 in EPS and $14.40 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=UAL" target="_blank" rel="noreferrer noopener"> after market hours</a>.
The stock is up 184.10% over the past year, 14.47% YTD.
Let&#8217;s look at what the charts indicate for United Airlines stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/01/43074340/jim-cramers-market-outlook-strong-earnings-trump-inauguration-and-whats-next-for-investors">Jim Cramer&#8217;s Market Outlook: Strong Earnings, Trump Inauguration, and What&#8217;s Next for Investors</a>
<h2 class="wp-block-heading">UAL Stock Chart Strongly Bullish Ahead Of Q4 Earnings&nbsp;</h2>
UAL stock is displaying a strongly bullish trend, with its share price of $109.36 trading above the five, 20 and 50-day exponential moving averages. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012125&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="629" height="487" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21125516/Screenshot-2025-01-21-at-11.19.20-PM.png" alt="" class="wp-image-743256" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21125516/Screenshot-2025-01-21-at-11.19.20-PM.png 629w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21125516/Screenshot-2025-01-21-at-11.19.20-PM-300x232.png 300w" sizes="(max-width: 629px) 100vw, 629px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012125&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
This indicates sustained buying pressure. The eight-day SMA (simple moving average) at $106.38, 20-day SMA at $101.57, and 50-day SMA at $97.15 all confirm a bullish setup, reinforcing momentum to the upside.
Additionally, UAL stock remains well above its 200-day SMA of $63.24, suggesting a long-term uptrend. The MACD (moving average convergence/divergence) indicator at 3.52 further signals bullish momentum, while the RSI (relative strength index) at 67.00 indicates strong buying interest but remains below overbought territory.
Overall, technical indicators support continued strength in UAL's price action.
<h2 class="wp-block-heading">United Airlines Analysts See 20% Upside</h2>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/UAL/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on United Airlines stock stands at a Buy with a price target of $93.51. The latest analyst ratings from JP Morgan, Susquehanna and UBS suggest a $131 average price target, implying a 19.51% upside for United Airlines&#8217; stock.
Price Action: United Airlines stock was trading 2% higher at $109.59 at the time of publication Tuesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/travel/25/01/42986606/us-global-investors-shines-in-2024-jets-etf-soars-33-amid-travel-boom-gold-shipping-funds-add-to-gains">US Global Investors Shines In 2024: JETS ETF Soars 33% Amid Travel Boom; Gold, Shipping Funds Add To Gains</a></li>
</ul>
Photo: Shutterstock

Earnings

Technicals

Previews

United Airlines Technical Signals Show Clear Skies Ahead Of Earnings

Scotiabank analyst Patrick Colville maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Sector Outperform and raises the price target from $205 to $225.

Price Target

Analyst Ratings

Scotiabank Maintains Sector Outperform on Zscaler, Raises Price Target to $225

Corning shares are trading higher after Citigroup raised its price target on the stock from $55 to $58.

Scotiabank analyst Patrick Colville maintains Tenable Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) with a Sector Perform and raises the price target from $44 to $45.

TENB

Scotiabank Maintains Sector Perform on Tenable Holdings, Raises Price Target to $45

Morgan Stanley analyst Joseph Moore upgraded Qorvo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) to Overweight from Equal-Weight, raising <a target="_blank" href="https://www.benzinga.com/quote/QRVO/analyst-ratings" rel="noreferrer noopener">the price forecast to $106 from $90.</a>
Moore notes that he has seen value in Qorvo stock and attempted to capture it through upgrades, but the results have been only modest.
The analyst also highlighted challenges in the radio frequency space, particularly with pressure on the Chinese business, which increases concentration in other areas.
Per Moore, while the radio frequency market served by high-performance companies like Broadcom, Skyworks Solutions, and Qorvo will continue to grow, it will remain highly concentrated, primarily driven by high-end global phones.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43097512/apples-ai-advances-cant-offset-chinese-market-slowdown-says-analyst" rel="noreferrer noopener">Apple&#8217;s AI Advances Can&#8217;t Offset Chinese Market Slowdown, Says Analyst</a>
With the involvement of activist Starboard, the analyst views that Qorvo has the potential for a renewed earnings recovery.
According to Moore, Qorvo can achieve $9.63 in EPS by shifting from a &#8220;growth through diversification&#8221; strategy to focusing on its core radio frequency proficiency from calendar year 2026.
The analyst sees 48.0% gross margins and 25.8% operating margins by 2026, both aligned with their pre-covid average from 2015-2019.
The analyst suggests that Qorvo could accomplish this by reducing, but not eliminating, internal fab usage to stabilize gross margins through cycles, realigning operating expenses around the core radio frequency portfolio, and leveraging its discounted multiple for cash return to accelerate EPS growth.
While there is potential for top-line growth, especially with the Apple Inc. modem transition, the analyst emphasizes that the EPS growth forecast does not depend on aggressive revenue assumptions. Given Starboard&#8217;s track record and history with Qorvo, the analyst sees a significant opportunity to unlock value through a strategic course correction.
Price Action: QRVO shares are trading higher by 5.75% to $89.05&nbsp;at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/asia/25/01/43088007/nvidia-apple-supplier-tsmc-halts-production-as-6-4-magnitude-earthquake-strikes-taiwan" target="_blank" rel="noreferrer noopener">Nvidia, Apple-Supplier TSMC Halts Production As 6.4 Magnitude Earthquake Strikes Taiwan</a></li>
</ul>

Analyst Color

Equities

Upgrades

Markets

General

AAPL

AVGO

QRVO

Qorvo Could Achieve $9.63 EPS By 2026 With Activist Involvement, Morgan Stanley Upgrades Stock

Curtiss-Wright shares are trading higher after the company announced it received a $27 million contract to provide aircraft handling systems and support for the U.S. Navy. Also, Citigroup initiated coverage on the stock with a Buy rating and announced a price target of $410.

Scotiabank analyst Patrick Colville maintains SolarWinds (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWI#NYSE">SWI</a>) with a Sector Perform and raises the price target from $13 to $15.

Scotiabank Maintains Sector Perform on SolarWinds, Raises Price Target to $15

Wall Street saw a strong preference for small and mid-cap equities, with the Russell 2000 index leading the market as investors bet on more domestic-friendly policies following Donald Trump's inauguration on Jan. 20 as <a href="https://www.benzinga.com/topic/donald-trump">the 47th U.S. president.</a>
The Russell 2000 rallied 1.7%, while other large-cap indices trailed behind. The Dow Jones, composed of non-tech blue-chip companies, rose by 1.2%, while both the S&amp;P 500 and the Nasdaq 100 edged up 0.9%.
Most sectors traded higher, except for energy. The announcement of a national energy emergency raised concerns about a fossil fuel oversupply, sending oil prices down more than 2%. WTI crude dropped to $72.10 per barrel.
In the Treasury market, yields fell as investors appeared convinced by Trump's pledges on inflation control and lower federal spending. The 10-year Treasury yield declined by five basis points to 4.58%.
One of the session's most notable moves came from Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), which plunged 4.3%, marking its worst trading day since early August 2024. The decline followed a downgrade by Jefferies, citing challenges in iPhone sales in China.
In commodities, gold climbed 1.2% to a two-month high, aiming for its ninth gain in the past eleven sessions, supported by lower Treasury yields. In the crypto space, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rebounded 3% to $106,000 after briefly touching $100,000 overnight amid the absence of crypto-related remarks from Trump on his first day in office.
<h1 class="wp-block-heading">Tuesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,314.89</td>
<td>1.7%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>43,995.44</td>
<td>1.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,053.00</td>
<td>0.9%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,630.38</td>
<td>0.9%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:20 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012125&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.9% to $602.64.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 1.1% to $439.55.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) edged 0.8% higher to $525.61.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 1.8% to $229.50.</li>
<li>The&nbsp;Industrials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>) outperformed, up 2%; the&nbsp;Energy Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 0.3%.</li>
</ul>
<h1 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h1>
<ul>
<li>Charles Schwab Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) rallied 4.7%, eyeing the strongest session in over two months, after reporting stronger-than-expected quarterly results. </li>
<li>Other stocks reacting to earnings included Prologis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>), up 6.4%; 3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>), up 5.5%; DR Horton Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>), down 0.4%; KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>), down nearly 5% and Fifth Third Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>), up 0.4%.</li>
<li>General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) soared by nearly 6% after Deutsche Bank upgraded the stock from Hold to Buy, and raised the price target from $56 to $60.</li>
<li>Companies slated to report earnings after the close include Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>), Interactive Brokers Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>), Capital One Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) and United Airlines Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>)</li>
</ul>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/25/01/43103527/mexican-peso-canadian-dollar-slide-as-trump-threatens-25-tariffs-expert-eyes-price-hikes-on-typical-us-breakfast">Mexican Peso, Canadian Dollar Slide As Trump Threatens 25% Tariffs, Economist Eyes Price Hikes On &#8216;Typical US Breakfast&#8217;</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Commodities

Treasuries

Global

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

FITB

IBKR

NFLX

SCHW

Small Caps Soar, Apple Slips, Treasury Yields Fall On Trump Day 2: What's Driving Markets Tuesday?

Scotiabank analyst Patrick Colville maintains Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) with a Sector Perform and raises the price target from $39 to $42.

Scotiabank Maintains Sector Perform on Rapid7, Raises Price Target to $42

Scotiabank analyst Patrick Colville maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Sector Outperform and raises the price target from $200 to $225.

PANW

Scotiabank Maintains Sector Outperform on Palo Alto Networks, Raises Price Target to $225

Scotiabank analyst Patrick Colville maintains Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) with a Sector Perform and lowers the price target from $96 to $94.

OKTA

Scotiabank Maintains Sector Perform on Okta, Lowers Price Target to $94

Ratings for Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Corteva and provided 12-month price targets. The average target is $68.58, accompanied by a high estimate of $73.00 and a low estimate of $62.00. This current average has increased by 2.36% from the previous average price target of $67.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1737486060_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Corteva is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benjamin Theurer</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$64.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$73.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$68.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$73.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$69.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$69.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Richard Garchitorena</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$69.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$68.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Benjamin Theurer</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$62.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Kristen Owen</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$71.00</td>
<td>$67.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Corteva. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Corteva compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Corteva's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Corteva's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CTVA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Corteva analyst ratings.</a>
<h2>Get to Know Corteva Better</h2>
Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva operates globally, but around half of revenue comes from North America.
<h3>Corteva: Delving into Financials</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Negative Revenue Trend: Examining Corteva's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -10.19% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Corteva's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -22.53%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -2.1%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Corteva's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.26%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.23.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTVA

12 Analysts Have This To Say About Corteva

ServiceNow shares are trading higher after JMP Securities raised its price target on the stock from $1000 to $1300.

Throughout the last three months, 12 analysts have evaluated Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Best Buy Co, presenting an average target of $102.5, a high estimate of $117.00, and a low estimate of $89.00. Highlighting a 5.02% decrease, the current average has fallen from the previous average price target of $107.92. 
<img src="https://www.benzinga.com/files/images/story/2025/1737486053_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Best Buy Co. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Seth Sigman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$89.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Steven Forbes</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$105.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Zachary Fadem</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$89.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$115.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$95.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Steven Zaccone</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$101.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Christopher Horvers</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$117.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Steven Zaccone</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$109.00</td>
<td>$115.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Best Buy Co. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Best Buy Co compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Best Buy Co's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BBY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Best Buy Co analyst ratings.</a>
<h2>About Best Buy Co</h2>
With $43.5 billion in consolidated 2023 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8.3% share of the North American market and north of 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid-19 pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
<h3>Best Buy Co: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Best Buy Co's revenue growth over a period of 3 months has faced challenges. As of 31 October, 2024, the company experienced a revenue decline of approximately -3.19%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 2.89%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Best Buy Co's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.82% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Best Buy Co's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.67% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Best Buy Co's debt-to-equity ratio surpasses industry norms, standing at 1.32. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 12 Analyst Ratings Have To Say About Best Buy Co

Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $271.1, a high estimate of $323.00, and a low estimate of $235.00. Surpassing the previous average price target of $230.75, the current average has increased by 17.49%.
<img src="https://www.benzinga.com/files/images/story/2025/1737486036_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Penumbra by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Priya Sachdeva</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$305.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$285.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Steve Lichtman</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$275.00</td>
<td>-</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$245.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$275.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Jason Mills</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$323.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$270.00</td>
<td>$232.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$235.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$248.00</td>
<td>$244.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Penumbra. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Penumbra compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Penumbra's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Penumbra's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PEN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Penumbra analyst ratings.</a>
<h2>About Penumbra</h2>
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
<h3>Penumbra: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Penumbra's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.11% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Penumbra's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 9.81%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Penumbra's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.61%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.96%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.21.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

10 Analysts Assess Penumbra: What You Need To Know

Providing a diverse range of perspectives from bullish to bearish, 17 analysts have published ratings on Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $39.71, a high estimate of $60.00, and a low estimate of $24.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 26.46%. 
<img src="https://www.benzinga.com/files/images/story/2025/1737486028_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Apellis Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$57.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$36.00</td>
<td>-</td>
</tr>
<tr>
<td>Judah Frommer</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$31.00</td>
<td>-</td>
</tr>
<tr>
<td>Colleen Kusy</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$51.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$36.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Justin Kim</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$57.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$47.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$60.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$39.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Apellis Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Apellis Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Apellis Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Apellis Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/APLS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Apellis Pharmaceuticals analyst ratings.</a>
<h2>About Apellis Pharmaceuticals</h2>
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
<h3>Apellis Pharmaceuticals's Economic Impact: An Analysis</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Positive Revenue Trend: Examining Apellis Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 78.29% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -29.19%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Apellis Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -22.91%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Apellis Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -6.36%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Apellis Pharmaceuticals's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.98, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLS

Analyst Expectations For Apellis Pharmaceuticals's Future

Truist Finl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>) short percent of float has fallen 20.92% since its last report. The company recently reported that it has 16.10 million shares sold short, which is 1.21% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.46 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Truist Finl Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737486024_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Truist Finl has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Truist Finl's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Truist Finl's peer group average for short interest as a percentage of float is 3.54%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(TFC) - Analyzing Truist Finl's Short Interest

In the last three months, 7 analysts have published ratings on Revvity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>), offering a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $140.86, a high estimate of $146.00, and a low estimate of $135.00. Observing a downward trend, the current average is 1.38% lower than the prior average price target of $142.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1737486021_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of Revvity by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$140.00</td>
<td>$146.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$138.00</td>
<td>-</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$144.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>Eve Burstein</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$146.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$138.00</td>
<td>$136.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Revvity. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Revvity compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Revvity's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Revvity's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RVTY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Revvity analyst ratings.</a>
<h2>Delving into Revvity's Background</h2>
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
<h3>Breaking Down Revvity's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Revvity's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.98% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Revvity's net margin is impressive, surpassing industry averages. With a net margin of 13.8%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Revvity's ROE excels beyond industry benchmarks, reaching 1.2%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Revvity's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.72%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Revvity's debt-to-equity ratio is below the industry average at 0.42, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RVTY

Forecasting The Future: 7 Analyst Projections For Revvity

XPeng's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) short percent of float has fallen 9.76% since its last report. The company recently reported that it has 44.60 million shares sold short, which is 5.92% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.57 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>XPeng Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737486018_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for XPeng has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing XPeng's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, XPeng's peer group average for short interest as a percentage of float is 8.90%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

XPEV

Looking Into XPeng's Recent Short Interest

Trump's tariffs are not priced in, and these stocks could be affected

Aptiv files for automatic mixed securities shelf

17:19 EST Aptiv (APTV) files automatic mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking...

Aptiv files automatic mixed securities shelf

3 Good Things About BlackBerry Q3 Earnings (Rating Upgrade)

Aptiv: Sensible Bet On Long-Term EV Penetration

Latest data shows the largest indicative borrow rate increases among liquid option names include: Aptiv (APTV) 54.26% +52.03, Nikola (NKLA) 147.81%...

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Mesoblast (MESO) 535.67% +298.96, Aptiv (APTV) 54...

Deckers Outdoor tops growth chart among S&P 500 consumer stocks in 2024

U.S. auto industry bracing for new trade and regulatory landscape

SA Charts: These companies are the biggest S&P 500 spenders on buybacks in Q3

ADBE

AISP

AMPX

CADL

CHPT

CROX

CRWD

DECK

DLTR

FAST

FBIN

FIVE

GOEV

GOOG

HNST

KULR

LULU

MEOBF

MESO

MSFT

NKLA

NVDA

RCAT

STLA

TNYA

WIMI

XLRE

YETI

Press Releases

Aptiv Reports Second Quarter 2024 Financial Results; Delivers Record Quarterly Operating Earnings and Earnings per Share; Announces New $5.0 Billion Share Repurchase Authorization and $3.0 Billion Accelerated Share Repurchase Program

Aptiv to Present at the Morgan Stanley Laguna Conference

Aptiv to Present at Goldman Sachs Communacopia + Technology Conference

Aptiv Announces Pricing of Senior Notes and Fixed-to-Fixed Reset Rate Junior Subordinated Notes

Aptiv to Release Third Quarter 2024 Financial Results

Aptiv Reports Third Quarter 2024 Financial Results

Aptiv Announces Leadership Appointments

Aptiv to Present at Barclays Global Automotive and Mobility Tech Conference

Aptiv to Present at UBS Global Industrials and Transportation Conference

Aptiv to Release Fourth Quarter 2024 Financial Results

Wells Fargo

Guggenheim

Morgan Stanley

Barclays

TD Cowen

뱅크오브아메리카는 2025년에 실적이 개선될 것으로 예상되는 주요 자동차 주식 3종목으로 페라리(RACE), 앱티브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) 및 오토네이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>)을 선정했다. 이들 기업은 최근의 변동성과 섹터 내 과제에도 불구하고 <a href="https://www.benzinga.com/news/contracts/25/01/42879460/honda-amazon-collaborate-on-ev-development-with-generative-ai-and-iot">자동차 산업의 지속적인 추세</a>로부터 혜택을 받을 수 있는 좋은 위치에 있다고 강조했다.
<h3>페라리: 탄력적인 럭셔리 및 브랜드 파워</h3>
페라리 주가는 2024년에 26% 상승하여 2023년 말 338달러에서 2024년 말 425달러로 높아졌다. 뱅크오브아메리카 애널리스트들은 브랜드 가치가 높은 럭셔리 자동차 제조업체로서의 입지를 강조하며 페라리에 대해 &#8216;매수&#8217; 투자의견을 유지했다. 제한된 생산량 증가, 가격 인상, 신모델 출시의 균형을 맞추는 이 회사의 전략은 지속적인 매출 및 수익 성장을 유지할 것으로 예상된다.
2025년 말 F80과 2026년 말 하이퍼카의 출시는 페라리의 레이싱 성능 향상과 함께 제품 믹스를 강화할 것으로 예상된다. S&amp;P는 페라리의 차량 차별화 및 운영 효율성 유지 능력을 강조하면서 재무 전망은 여전히 보수적이라고 지적했다. 애널리스트들은 불확실한 거시 경제 상황에서도 페라리의 수익 회복력이 내년 주식 실적을 견인할 핵심 강점이라고 보고 있다.
<h3>앱티브: 반등을 위한 포지셔닝</h3>
앱티브의 주가는 2023년 말 90달러에서 2024년 말 60달러로 33% 하락했다. 이러한 하락에도 불구하고 뱅크오브아메리카 애널리스트들은 회복 기회를 보고 주식에 대해 &#8216;매수&#8217; 의견을 유지했다. 하락은 주로 전기차 판매 둔화, 중국 자동차 업체와의 경쟁 심화, 주요 고객사의 생산량 감소로 인해 발생했다.
그러나 애널리스트들은 앱티브에 대한 역풍은 일시적인 현상이라고 주장한다. 차량 아키텍처와 연결성에 대한 앱티브의 전문성은 제조 공정을 간소화하려는 자동차 제조업체의 노력과 맞물려 있다. 뱅크오브아메리카는 앱티브의 성장률이 2026년에서 2027년 사이에 다시 가속화되어 수익과 밸류에이션이 회복될 것으로 예상한다.
<h3>오토네이션: 업계 모멘텀 활용</h3>
오토네이션 주가는 2024년에 13% 상승하여 150달러에서 170달러로 올랐다. 뱅크오브아메리카 애널리스트들은 팬데믹 이후 구조적 개선과 강력한 잉여현금흐름 창출 능력을 언급하며 이 회사를 긍정적으로 보고 있다. 이러한 재무 건전성을 바탕으로 오토네이션은 사업 이니셔티브에 재투자하고 자사주를 매입하며 지속적인 미국 신차 판매 회복의 혜택을 누릴 수 있다.
애널리스트들은 2025년 말 또는 2026년까지 신차 대당 매출 총이익이 높은 수준으로 안정화되어 오토네이션의 수익 모멘텀을 뒷받침할 것으로 예상하고 있다. 또한 회사의 판관비(SG&amp;A) 레버리지도 견조한 수준을 유지할 것으로 예상된다. 이러한 긍정적인 요인에도 불구하고 오토네이션은 향후 12개월 주가수익비율이 약 9.2배로 과거 평균 13배에 비해 할인된 가격에 거래되고 있으며, 동종업계 평균과 비교해도 낮은 수준이다. 애널리스트들은 이러한 저평가가 매력적인 투자 사례를 제공한다고 생각한다.
자동차 부문 전체에 대한 인사이트: 뱅크오브아메리카는 가처분 소득 대비 차량 결제액이 적정 수준이며, 신차 및 중고차 가격이 모두 안정화되었다고 언급했다. 최신 모델의 중고차 공급이 제한되어 있다는 점도 가격 상승을 뒷받침할 것이다. 또한 과잉 생산과 전기 및 자율주행 차량으로의 전환과 같은 과제를 고려할 때 자동차 산업 내 통합의 필요성을 강조했다.
그리고 자율주행 차량의 발전으로 인해 개발 및 배포를 간소화하기 위한 연방 규제 프레임워크의 필요성이 커질 것으로 예측하고 있다. 이러한 규제의 명확성은 기술의 광범위한 채택을 촉진하는 데 도움이 될 것이다.
이미지 출처: Flickr
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

<h3 class="wp-block-heading">새로 등장한 블록</h3>
에볼런트 헬스(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/evh" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for EVH">EVH</a>)가 <a href="https://www.benzinga.com/m-a/24/08/40529349/evolent-health-explores-sale-garners-inbound-interest-from-private-equity-firms" target="_blank" rel="noopener" data-google-interstitial="false">매물로 나온 것</a>으로 알려졌다. 버지니아 주 알링턴에 본사를 둔 이 소프트웨어 회사는 인수 문의를 받은 후 경매 프로세스를 시작했다. 잠재적인 구혼자 중에는 TPG(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/tpg" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for TPG">TPG</a>), 클레이톤, 듀블리에 &amp; 라이스(Clayton, Dubilier &amp; Rice), KKR &amp; 컴퍼니(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/kkr" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for KKR">KKR</a>)가 있다. 로이터는 건강 보험사 엘레반스 헬스(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/elv" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for ELV">ELV</a>)가 한 사모 펀드 파트너와 협력하여 거래를 추진할 수 있다고 보고했다.
<div class="sc-grPMMF hjTkfb ticker-box-wrapper">암 치료제 개발에 주력하는 기업인 크로노스 바이오(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/kron" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for KRON">KRON</a>)가 인수나 합병 등 &#8216;전략적 대안&#8217;을 모색하고 있다. 캘리포니아주 샌머테이오에 본사를 둔 크로노스 바이오는 9월 30일 현재 1억 2,490만 달러의 현금 보유고를 보고했다.</div>
<div>
생고뱅(OTCPK:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/codgf" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for CODGF">CODGF</a>) (OTCPK:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/codyy" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for CODYY">CODYY</a>)은 <a href="https://www.bloomberg.com/news/articles/2024-11-13/st-gobain-is-said-to-weigh-2-5-billion-sale-of-auto-glass-unit" target="_blank" rel="noopener">블룸버그</a>에 따르면 최대 25억 유로(26억 달러)에 달하는 자동차 유리 사업부 매각을 고려하고 있다. 이 회사는 광범위한 비즈니스 평가의 일환으로 이러한 전략적 움직임을 고려하고 있는 것으로 알려졌다. 이번 매각은 운영을 간소화하고 핵심 사업 분야에 집중하려는 생고뱅(Saint-Gobain)의 노력과 일치한다.
쉘(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/shel" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for SHEL" data-google-interstitial="false">SHEL</a>)은 탄소 상쇄 포트폴리오의 대부분을 <a href="https://www.bloomberg.com/news/articles/2024-11-13/shell-aims-to-sell-majority-stake-in-carbon-offsets-business?srnd=phx-deals" target="_blank" rel="noopener">폐기하려고</a> 한다. 이 회사는 <a href="https://www.bloomberg.com/news/features/2023-08-31/shell-silently-abandoned-its-100-million-a-year-plan-to-offset-co2-emissions" target="_blank" rel="noreferrer noopener">2018</a>년에 수십 개의 프로젝트를 포괄하는 오프셋 포트폴리오를 처음 출시했다.
</div>
유니레버(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UL#NYSE">UL</a>)는 우녹스(Unox) 수프, 코니멕스(Conimex) 조미료 등 일부 네덜란드 식품 브랜드의 판매를 모색하고 있다. 로이터에 따르면 회사는 대신 자사의 가장 큰 &#8216;파워&#8217; 라벨에 집중할 것이라고 한다.
<h3 class="wp-block-heading">파산 블록</h3>
알렉스 존스(Alex Jones)의 미디어 회사인 인포워스(Infowars)가 디 어니언(The Onion)에 인수되었다는 소식이다. 이 거래의 뒷받침은 <a href="https://www.benzinga.com/media/24/11/41982446/jokes-on-jones-onion-backed-by-families-of-sandy-hook-victims-buys-info-wars" target="_blank" rel="noopener" data-google-interstitial="false">샌디 훅(</a><a href="https://www.benzinga.com/media/24/11/41982446/jokes-on-jones-onion-backed-by-families-of-sandy-hook-victims-buys-info-wars" target="_blank" rel="noopener" data-google-interstitial="false">Sandy Hook</a><a href="https://www.benzinga.com/media/24/11/41982446/jokes-on-jones-onion-backed-by-families-of-sandy-hook-victims-buys-info-wars" target="_blank" rel="noopener" data-google-interstitial="false">) 피해자</a> 가족들로, 이들은 존스가 10억 달러 이상의 명예훼손 판결을 지고 있는 상황에서 이 거래를 시가에 상징적 정의라고 찬양했다. 일론 머스크 및 터커 칼슨 등 우파 인사들의 <a href="https://www.benzinga.com/news/23/12/36168941/elon-musks-controversial-move-alex-jones-returns-to-x-after-user-vote" target="_blank" rel="noopener" data-google-interstitial="false">동정을 받아온</a> 존스는 눈에 띄게 괴로워하는 소셜 미디어 영상을 통해 &#8220;민주당&#8221;을 비난하며 인수를 확인했다.
다이아몬드 스포츠 그룹(Diamond Sports Group)의 구조 조정에는 부채를 약 90억 달러에서 2억 달러로 줄이는 것이 포함될 것이라고 <a href="https://www.espn.com/mlb/story/_/id/42388454/diamond-sports-group-emerges-bankruptcy" target="_blank" rel="noopener">ESPN</a>이 보도했다. 구조조정 계획은 다이아몬드가 부채 보유자들로부터 &#8220;거의 만장일치의 지지&#8221;로 분류한 것을 받았다. 현재 1억 달러의 유동성을 보유하고 있는 다이아몬드는 파산 상태에서 벗어나 독립 기업으로 운영될 예정이다. 모회사인 싱클레어(Sinclair)는 2019년에 폭스(Fox)로부터 지역 채널을 106억 달러에 인수하기 위해 80억 달러의 빚을 졌다. 그 빚은 다이아몬드의 파산에 기여했다.
<h3 class="wp-block-heading">블록의 업데이트</h3>
현재 휴마나(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/hum" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for HUM" data-google-interstitial="false">HUM</a>)가 적극적으로 매각을 추진하고 있다는 구체적인 징후는 없다. 시그나 그룹(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/ci" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for CI" data-google-interstitial="false">CI</a>)이 휴마나를 인수한다는 최근 추측이 확실하게 해결되었으며, 시그나는 현재로서는 휴마나와의 <a href="https://www.benzinga.com/general/health-care/24/11/41877573/cigna-not-pursuing-humana-merger-stock-soars" target="_blank" rel="noopener" data-google-interstitial="false">합병을 추진하지 않는다</a>고 명시적으로 밝혔다. 이러한 해명은 새로운 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41979935/golden-years-for-ma-deals-ahead-under-trump-analysts-highlight-top-10-large-cap-candidates" target="_blank" rel="noopener" data-google-interstitial="false">공화당 행정부와 의회</a> 하에서 보다 관대한 독점 금지 검토가 이루어질 가능성에 따라 선거 후 소문이 다시 불붙은 후에 나온 것이다.
스피릿 항공(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/save" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for SAVE" data-google-interstitial="false">SAVE</a>)는 더 이상 프론티어 항공(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/ulcc" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for ULCC" data-google-interstitial="false">ULCC</a>)과 거래 협상을 진행하지 않는다. 현재 파산 계획을 확정하기 위해 채권 보유자와 사전 논의가 진행 중이다. 이 항공사는 계속해서 증가하는 손실과 다가오는 부채 만기 문제로 어려움을 겪고 있다. <a href="https://www.benzinga.com/news/earnings/24/11/41932146/spirit-airlines-nears-bankruptcy-creditors-may-approve-equity-cancellation-heres-what-it-means-for-investors-as-shares-fall-with-a-thud" target="_blank" rel="noopener" data-google-interstitial="false">월스트리트 저널</a>에 따르면 파산 신청은 몇 주 안에 이뤄질 것으로 예상된다.
<div class="ticker-wrapper">
<div class="sc-grPMMF hjTkfb ticker-box-wrapper">
메이 파마(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/meip" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for MEIP" data-google-interstitial="false">MEIP</a>)는 계속해서 M&amp;A 기회를 모색하고 있으며 오펜하이머(Oppenheimer &amp; Co., Inc.)를 전담 재무 자문사로 고용하여 프로세스를 지원한다. 2025회계연도 1분기 동안 회사는 인력 감축을 포함한 현금 보존 노력을 시작했으며, 이는 회사의 운영 및 전략 방향이 발전함에 따라 단계적으로 계속될 것이다.
<h3 class="wp-block-heading">블록에서의 메모</h3>
월스트리트는 공화당이 의회를 장악하고 규제를 완화함에 따라 M&amp;A가 급증할 것으로 예상하고 있다. 분석가들은 리나 칸(Lina Khan) 연방거래위원회(FTC) 위원장의 해임으로 인해 독점 금지 조사가 쉬워질 것으로 예상하고 있다. 뱅크 오브 아메리카는 도널드 트럼프 대통령 당선자와 같은 공화당 행정부가 역사적으로 민주당 행정부에 비해 금융 부문 M&amp;A 활동을 50% 이상 육성했다는 점을 강조한다.
뱅크 오브 아메리카는 또한 금리 인하가 발효되고 경제 상황이 안정화됨에 따라 2025년은 M&amp;A에 있어 더 좋은 해가 될 수 있다고 예측한다. 다음은 은행이 수집한 5가지 잠재적 목표 목록이다. <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41979935/golden-years-for-ma-deals-ahead-under-trump-analysts-highlight-top-10-large-cap-candidates" target="_blank" rel="noopener" data-google-interstitial="false">전체 목록</a>을 보려면 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41979935/golden-years-for-ma-deals-ahead-under-trump-analysts-highlight-top-10-large-cap-candidates" target="_blank" rel="noopener" data-google-interstitial="false">여기를 클릭</a>하세요.
<table class="block core-block table" style="height: 336px;" width="895">
<thead>
<tr>
<th>회사</th>
<th>섹터</th>
<th>시가 총액 ($M)</th>
<th>기업 가치 대비 잉여 현금 흐름 (%)</th>
<th>장기 성장 기대치 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>유니버셜 헬스 서비스 (NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/uhs" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for UHS" data-google-interstitial="false">UHS</a>)</td>
<td>헬스케어</td>
<td>13,932</td>
<td>4.4</td>
<td>25.3</td>
</tr>
<tr>
<td>랄프 로렌 (NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/rl" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for RL" data-google-interstitial="false">RL</a>)</td>
<td>소비재</td>
<td>12,473</td>
<td>5.99</td>
<td>10.5</td>
</tr>
<tr>
<td>파라마운트 글로벌 (NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/para" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for PARA" data-google-interstitial="false">PARA</a>)</td>
<td>통신 서비스</td>
<td>7,250</td>
<td>3.4</td>
<td>46.4</td>
</tr>
<tr>
<td>자빌 (NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/jbl" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for JBL" data-google-interstitial="false">JBL</a>)</td>
<td>기술</td>
<td>14,480</td>
<td>6.39</td>
<td>12.7</td>
</tr>
<tr>
<td>해즈브로 (NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/has" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for HAS" data-google-interstitial="false">HAS</a>)</td>
<td>소비재</td>
<td>9,215</td>
<td>3.6</td>
<td>27.5</td>
</tr>
</tbody>
</table>
</div>
</div>
지난주 딜 디스패치를 ​​보려면 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%94%9C-%EB%94%94%EC%8A%A4%ED%8C%A8%EC%B9%98-%EC%84%A0%EA%B1%B0-%EC%9D%B4%ED%9B%84-%EA%B5%90%EB%8F%84%EC%86%8C-%ED%9A%8C%EC%82%AC%EB%93%A4%EC%97%90-%EC%B4%88%EC%A0%90-%ED%8A%B8%EB%A6%BD%EC%96%B4/" target="_blank" rel="noopener">여기를 클릭</a>하세요.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 슈퍼 마이크로 컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)의 주식은 독립 감사인인 언스터 &amp; 영(Ernst &amp; Young)의 <a href="https://www.benzinga.com//node/41646425" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">사임</a> 소식이 전해진 후 44.89% 하락했다. 아거스 리서치(Argus Research)는 <a href="https://www.benzinga.com//node/41661361" target="_blank" rel="noreferrer noopener">매수에서 보유로 등급</a>을 하향 조정했다.
2. 에스티 로더(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>)의 주식은 1분기 실적을 발표한 후 여러 애널리스트가 <a href="https://www.benzinga.com//node/41653721" target="_blank" rel="noreferrer noopener">주가 전망을 하향 조정</a>하면서 23.69% 하락했다.
3. 앱티브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>)의 주식은 <a href="https://www.benzinga.com//node/41657841" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">3분기 매출</a>이 예상보다 저조하게 나타난 후 18.67% 하락했다.
4. 샤크닌자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SN#NYSE">SN</a>)의 주식은 <a href="https://www.benzinga.com//node/41648658" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">3분기 재무 실적</a>을 발표한 후 18.48% 하락했다.
5. 체크 포인트 소프트웨어(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>)의 주식은 예상보다 저조한 매출 실적을 발표한 후 17.70% 하락하고, 애널리스트들이 <a href="https://www.benzinga.com//node/41637268" target="_blank" rel="noreferrer noopener">주가 전망과 등급을 수정</a>했다.
6. 코닌클리케 필립스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>)의 주식은 <a href="https://www.benzinga.com//node/41570381" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">3분기 실적 부진</a>과 중국 내 수요 약화로 연간 전망을 수정 발표한 후 16.36% 하락했다.
7. 모노리식 파워시스템(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>)의 주식은 <a href="https://www.benzinga.com//node/41635566" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">3분기 재무 실적</a> 발표 후 15.75% 하락했다.
8. CDW(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDW#NASDAQ">CDW</a>)의 주식은 하드웨어 수요 부진과 고객 지연으로 <a href="https://www.benzinga.com//node/41630458" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">3분기 실적</a>이 예상보다 저조하게 나타난 후 13.19% 하락했다.
9. 보르 드릴링(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BORR#NYSE">BORR</a>)의 주식은 3분기 예비 재무 실적 부진으로 계속 하락세를 보이며 13.19% 하락했다. 2024년 12월 31일자로 회사 주식은 오슬로 증권 거래소에서 자발적으로 상장 폐지된다.
10. 리 오토(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>)의 주식은 분기 <a href="https://www.benzinga.com//node/41683552" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">실적과 10월 인도량</a>을 발표한 후 12.96% 하락했다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%A0%88%EB%94%A7-%EB%A1%9C%EB%B8%94%EB%A1%9D%EC%8A%A4-%EB%B0%8F-%EA%B0%80%EB%AF%BC%EC%9D%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC%EC%A4%80-10/" target="_blank" rel="noopener">레딧, 로블록스 및 가민은 지난주 최고 성과를 보여준 10개 대형주 중 일부 (10월 28일-11월 1일)</a></li>
</ul>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)의 CEO인 일론 머스크는 수년 동안 운전자가 필요 없는 차량이 승객을 한 곳에서 다른 곳으로 데려다 줄 수 있기를 꿈꿔왔다. 목요일에는 머스크의 비전이 실현될 가능성이 있는 <a href="https://www.benzinga.com/trading-ideas/24/10/41274987/how-to-watch-tesla-robotaxi-day-live-elon-musks-autonomous-vehicle-event-is-here">테슬라 로보택시</a>의 공개가 있을 수 있다.
그러나 새로운 설문 조사에 따르면, 수요와 소비자 신뢰 측면에서 로보택시는 대량 채택을 위한 준비가 되어 있지 않을 수 있다.
무슨 일이 (What Happened): J.D. 파워의 새로운 소비자 설문 조사에서는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41212796/tesla-robotaxi-day-preview-move-over-autonomous-vehicles-analyst-says-this-positive">자율주행차</a>에 탑승한 승객들의 경험과 평가를 테스트했다.
2024년 미국 로보택시 경험 연구에 <a href="https://www.jdpower.com/business/press-releases/2024-us-robotaxi-experience-study">따르면</a>, 소비자들은 10점 만점에 평균 8.53의 만족도를 보였다.
8월에 진행도니 이 연구는 승차의 편안함과 편리함, 탑승 시작, 차량 내 탑승, 서비스 이용 가능성 및 비용, 차량 기술의 5가지 범주를 기반으로 했다. 이 5개 범주 중에서 기술 점수가 가장 높았다.
로보택시에 탑승한 소비자들은 완전 자동화된 자율주행차에 대해 76%의 소비자 신뢰 점수를 받았다. 이 점수는 상대적으로 높은 편이지만, 로보택시에 탑승하지 않은 사람들의 완전 자동화된 자율주행차에 대한 소비자 신뢰 점수는 20%에 불과했다.
이상적인 로보택시 서비스를 설명해달라는 질문에 응답자들은 안전성을 가장 중요하게 생각하며 78%가 이를 선택했다. 그 다음으로 신뢰성과 신뢰성이 각각 71%와 66%로 나타났다.
설문에서 소비자들이 가장 요청한 사항 중 하나는 로보택시에 지역 긴급 서비스와 연결할 수 있는 비상 버튼을 제공하는 것이었다. 그 외에도 안전 기능에 따라 차량을 선택할 수 있는 옵션과 사전에 경로를 설정할 수 있는 요청이 있었다.
보고서에 언급된 차량 테스트를 거친 회사들은 다음과 같다:
<ul>
<li>크루즈(Cruise), 이는 제너럴 모터스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>)가 대주주인 회사이다.</li>
<li>메이 모빌리티(May Mobility)</li>
<li>모셔널(Motional), 이는 현대 자동차(OTC:<a class="ticker" href="https://www.benzinga.com/stock/HYMLF#OTC">HYMLF</a>)와 앱티브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>)의 합작 회사이다.</li>
<li>웨이모(Waymo), 이는 알파벳(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)의 자회사이다.</li>
<li>죽스(Zoox), 이는 아마존닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)의 자회사이다.</li>
</ul>
이번 연구는 댈러스, 라스베이거스, 로스앤젤레스, 피닉스, 샌프란시스코 등 5개 시장에서 이루어졌다.
매그니피센트 7의 CEO들이 주식을 매도할 때 당신은 매수하고 있습니까?
<ul>
<li>우리의 내부 거래 페이지를 통해 정보를 얻으세요 — <a href="https://www.benzinga.com/sec/insider-trades/">마크저커버그, 일론 머스크 및 젠슨 황과 같은 리더들이 자신의 주식을 매도할 때를 확인하세요.</a></li>
</ul>
왜 중요한가요 (Why It&#8217;s Important): 이 연구는 일부 대도시에서 로보택시를 경험한 소비자들에 대해 상대적으로 높은 신뢰도와 만족도를 발견했다. 이러한 도시들에서는 기술이 승인되었거나 테스트 중이다.
이 보고서의 또 다른 시사점은 로보택시가 있는 도시에서 살고 소비자 인식이 높아지면 기술에 대한 신뢰가 향상될 수 있다는 것이다. 연구에 따르면, 로보택시에 탑승하지 않은 사람들의 소비자 신뢰도는 34%로, 로보택시가 운영되는 도시들에 거주하는 경우에도 신뢰도가 높아졌다.
&#8220;로보택시 세그먼트는 여전히 모든 사람의 게임이다. 대부분의 사람들은 로보택시 브랜드에 익숙하지 않고 명확한 연상 이미지를 형성하지 않았기 때문이다&#8221;라고 J.D. 파워의 사용자 경험 벤치마킹 및 기술 수석 이사 캐슬린 리즈크(Kathleen Rizk)가 말했다.
리즈크는 로보택시를 운영하는 회사들이 &#8220;자신들의 배치 시장을 넘어 모든 소비자에게 교육하고 신뢰를 구축할 수 있는 방법을 찾아야 한다&#8221;고 덧붙였다.

다음 읽어보기:
<ul>
<li><a href="https://www.benzinga.com/general/education/24/10/41166723/how-many-evs-has-tesla-delivered-produced-each-quarter-a-look-at-the-results-since-2019" target="_blank" rel="noreferrer noopener">테슬라가 매 분기마다 얼마나 많은 EV를 인도하고 생산했습니까? 2019년 이후 결과를 살펴보세요.</a></li>
</ul>
이미지는 인공지능을 사용하여 Midjourney로 생성되었습니다.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Tech

AMZN

GOOGL

HYMLF

TLSA

일론 머스크가 테슬라의 로보택시를 공개, 새 연구에서 회의론과 신뢰 구축의 필요성 대두

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>월그린스 부츠 얼라이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>)의 주가는 회사가 혼합된 3분기 실적을 보고하고 2024년 지침을 <a href="https://www.benzinga.com//node/39523397" target="_blank" rel="noreferrer noopener">컨센서스 추정치</a>보다 낮게 낮춘 후 24.12% 하락했다. 분석가들은 주식에 대한 <a href="https://www.benzinga.com/quote/wba/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">가격 예측</a>을 하향 조정했다.</li>
<li>플로어 앤 데코 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FND#NYSE">FND</a>)의 주식은 예상보다 나쁜 5월 주택판매 경제 데이터에 대한 반응으로 13.41% 급락했다.</li>
<li>모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)의 주가는 회사의 RSV 백신이 <a href="https://www.benzinga.com//node/39508239" target="_blank" rel="noreferrer noopener">50%의 효능을 보인</a> 이후 11.76% 급락했다.</li>
<li>버켄스탁 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>)의 주식은 회사가 매각 주주가 최대 1,400만 주 보통주를 <a href="https://www.benzinga.com//node/39467369" target="_blank" rel="noreferrer noopener">공모</a>한다고 발표한 후 주가는 10.86% 하락했다.</li>
<li>베이진(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGNE#NASDAQ">BGNE</a>)의 주식은 지난주에 9.70% 하락했다.</li>
<li>풀 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/39484866" target="_blank" rel="noreferrer noopener">FY24 EPS 가이던스를 낮춘 </a>이후 9.19% 떨어졌다.</li>
<li>징동닷컴(JD닷컴)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>)의 주식은 미국이 <a href="https://www.benzinga.com//node/39521291" target="_blank" rel="noreferrer noopener">중국 기술에 대한 투자</a>를 억제하는 규정을 발표한 이후 8.89% 하락했다.</li>
<li>에코페트롤(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EC#NYSE">EC</a>)의 주식은 8.02% 급락했다</li>
<li>인터내셔널 페이퍼(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IP#NYSE">IP</a>)의 주식은 수자노(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUZ#NYSE">SUZ</a>)가 <a href="https://www.benzinga.com//node/39519611" target="_blank" rel="noreferrer noopener">인수 거래를 중단</a>하기로 한 이후 7.98% 하락했다.</li>
<li>마이크론 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)의 주식은 지난 주 <a href="https://www.benzinga.com//node/39520174" target="_blank" rel="noreferrer noopener">3분기 실적과 4분기 전망</a>에 대한 정보가 나온 이후 7.62% 하락했다.</li>
</ol>
다음 기사 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/%eb%a6%ac%eb%b9%84%ec%95%88%ea%b3%bc-%ec%b9%b4%eb%b0%94%eb%82%98%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-10%eb%8c%80-%eb%8c%80/" target="_blank" rel="noopener">리비안과 카바나는 지난주 최고의 성과를 보인 10대 대형주 중 일부 (6월 23일-6월 29일)</a></li>
</ul>
촬영: Shutterstock의 Lutsenko_Oleksandr

BGNE

BIRK

MRNA

POOL

모더나와 월그린스는 지난주 최악의 성과를 보인 10대 대형주 중 일부 (6월 23일-6월 29일)

Comments

Aptiv

뉴스

에 대한 최신 뉴스 Aptiv (NYSE:APTV) 주식

수요일, 1월 15, 2025

일요일, 11월 17, 2024

일요일, 11월 03, 2024

금요일, 10월 11, 2024

일요일, 6월 30, 2024

뉴스

파트너 / 기고자

벤징가 글로벌